ctDNA for MRD assessment is prognostic and predictive in newly diagnosed and relapsed/refractory lymphoma.
Blood tests detecting cancer DNA after treatment predict survival better than imaging, potentially enabling earlier intervention in lymphoma patients.
EOT ctDNA-MRD positivity is the strongest predictor of inferior event-free survival in lymphoma (HR 37.10, 95% CI 6.20-221.8), outperforming PET (HR 5.88), in the largest real-world cohort to date (n=144, personalized Signatera assay). This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- multicenter_retrospective_cohort
- Category
- early_cancer_detection
- Maturity
- Potentially Practice-Changing
- Journal
- Blood Neoplasia
Why it surfaced
Largest real-world ctDNA-MRD lymphoma cohort; HR 37.10 vs PET HR 5.88 — clinically transformative MRD signal; open-access ASH journal; directly addresses T1 and T3 watchlist priorities.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.